Nicacio Leonardo Viana reported grant involving 58,333 shares of Corbus Pharmaceuticals Holdings, Inc. at $0.00 for $0 on Aug 16, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Medical Officer
Chief Medical Officer
Filed Aug 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
58,333Common Stock, par value $0.0001 per share
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
58,333Direct
Trade date
Aug 16, 2026Grant
Filed
Aug 17, 2026, 4:30 PM ET1-day reporting delay
Accession
0001193125-26-354145Code A · Transaction 543
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 16, 2026Grant191,676$0.00$0Trade 544
2 transaction rows in this filing. Joint filers share the same rows.

CRBP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CRBP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −14%1w ago −3.1%1d ago −3.8%
Returns since7d +1.9%30d −34%90d180d1y

Footnotes in full

F1: On August 16, 2026, the Reporting Person was granted 58,333 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on August 16, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardee's termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service. F2: This amount includes 58,333 unvested RSUs granted on August 16, 2026. F3: This option award was made in accordance with the terms of the issuer's 2026 Inducement Award Plan. 25% of the option vests on August 3, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on September 3, 2027.